Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small
Crossref DOI link: https://doi.org/10.1007/s12029-022-00804-4
Published Online: 2022-01-17
Published Print: 2023-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mengato, Daniele http://orcid.org/0000-0003-1374-1505
Chiumente, Marco
Messori, Andrea
Text and Data Mining valid from 2022-01-17
Version of Record valid from 2022-01-17
Article History
Accepted: 8 January 2022
First Online: 17 January 2022
Declarations
:
: The authors declare no competing interests.